v3.25.4
REVENUES (Tables)
 12 Months Ended
Dec. 31, 2025
Revenue from Contract with Customer [Abstract]  
Summary of Disaggregation of Revenue
The following table summarizes our Total revenues:
Year Ended December 31, 2025Year Ended December 31, 2024Year Ended December 31, 2023
(in millions)U.S.
Europe(6)
Rest of World(6)
TotalU.S.
Europe(6)
Rest of World(6)
TotalU.S.
Europe(6)
Rest of World(6)
Total
Product sales:
HIV
Biktarvy$11,467 $1,676 $1,190 $14,334 $10,855 $1,509 $1,060 $13,423 $9,692 $1,253 $905 $11,850 
Descovy2,559 93 105 2,758 1,902 100 110 2,113 1,771 100 114 1,985 
Genvoya1,281 148 69 1,498 1,498 180 84 1,762 1,752 205 103 2,060 
Odefsey881 246 40 1,167 957 290 41 1,288 1,012 294 44 1,350 
Symtuza - Revenue share(1)
363 120 12 495 450 130 12 592 382 133 13 529 
Other HIV(2)
352 109 40 500 257 129 48 434 238 116 47 401 
Total HIV 16,904 2,392 1,456 20,752 15,918 2,339 1,355 19,612 14,848 2,102 1,226 18,175 
Liver Disease
Sofosbuvir/Velpatasvir(3)
636 292 344 1,272 922 299 374 1,596 859 323 355 1,537 
Vemlidy507 49 514 1,070 486 44 428 959 410 38 414 862 
Other Liver Disease(4)
476 330 69 874 192 202 73 467 152 150 83 385 
Total Liver Disease1,619 671 927 3,217 1,601 545 876 3,021 1,421 511 852 2,784 
Veklury470 151 290 911 892 284 623 1,799 972 408 805 2,184 
Oncology
Cell Therapy
Tecartus153 158 32 344 234 138 31 403 245 110 15 370 
Yescarta595 598 303 1,495 662 666 242 1,570 811 547 140 1,498 
Total Cell Therapy748 755 335 1,839 896 804 274 1,973 1,055 658 156 1,869 
Trodelvy877 347 173 1,397 902 294 119 1,315 777 217 68 1,063 
Total Oncology1,626 1,102 508 3,236 1,798 1,098 393 3,289 1,833 875 224 2,932 
Other
AmBisome20 267 221 509 44 276 212 533 43 260 189 492 
Other(5)
177 32 81 290 255 34 68 356 261 40 66 367 
Total Other197 300 302 799 299 310 280 889 304 301 255 859 
Total product sales20,816 4,617 3,483 28,915 20,508 4,576 3,526 28,610 19,377 4,197 3,361 26,934 
Royalty, contract and other revenues60 447 20 527 82 58 4 144 62 114 7 182 
Total revenues$20,876 $5,064 $3,503 $29,443 $20,591 $4,634 $3,529 $28,754 $19,438 $4,310 $3,368 $27,116 
_______________________________
(1)    Represents our revenue from cobicistat (“C”), emtricitabine (“FTC”) and tenofovir alafenamide (“TAF”) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (“Janssen”). See Note 7. Collaborations and Other Arrangements for additional information.
(2)    Includes Atripla, Complera/Eviplera, Emtriva, Stribild, Sunlenca, Truvada, Tybost and Yeztugo/Yeytuo.
(3)    Includes Epclusa and the authorized generic version of Epclusa sold by Gilead’s separate subsidiary, Asegua.
(4)    Includes ledipasvir/sofosbuvir (Harvoni and the authorized generic version of Harvoni sold by Asegua), Hepcludex, Hepsera, Livdelzi/Lyvdelzi, Sovaldi, Viread and Vosevi.
(5)    Includes Cayston, Jyseleca, Letairis and Zydelig.
(6)    All individual international locations accounted for less than 10% of Total revenues.
Summary of Revenues from Major Customers
The following table summarizes the revenues from each of our customers who individually accounted for 10% or more of our total gross product sales:
Year Ended December 31,
(as a percentage of total gross product sales)202520242023
Cardinal Health, Inc. (“Cardinal Health”)29 %29 %28 %
Cencora, Inc. (“Cencora”)21 %21 %22 %
McKesson Corporation (“McKesson”)24 %23 %24 %
Summary of Revenues Recognized from Performance Obligations Satisfied in Prior Periods
The following table summarizes revenues recognized from performance obligations satisfied in prior years:
Year Ended December 31,
(in millions)202520242023
Revenue share with Janssen(1) and royalties for licenses of intellectual property
$612 $727 $680 
Changes in estimates(2)
$903 $452 $340 
_______________________________
(1)    See Note 7. Collaborations and Other Arrangements for additional information.
(2)    Changes in estimates increased during the year ended December 31, 2025 primarily due to recognition of $400 million in the third quarter of previously constrained revenues from the sale of certain intellectual property.
Summary of Contract Balances
The following table summarizes our contract balances:
December 31,
(in millions)20252024
Contract assets(1)
$629 $277 
Contract liabilities(2)
$48 $58 
_______________________________
(1)    The increase in contract assets during the year ended December 31, 2025 primarily related to recognition of $400 million in the third quarter of previously constrained revenues from the sale of certain intellectual property.
(2)    Future revenues recognized from contract liabilities are not expected to be material in any one year.